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Abstract
Purpose StatementMagnesium Sulfate has been used as a multimodal approach for analgesia as it may reduce opioid consumption in 
the first 24 hours after surgery and decrease post-operative pain scores.
Introduction
The use of intraoperative opioids for analgesia is associated with postoperative side effects such as respiratory 
depression, ileus, nausea, and vomiting. The side effects from opioids can prolong hospital stay and cause patient 
dissatisfaction. Magnesium acts as a N-methyl-D-aspartate (NMDA) receptor antagonist resulting in an analgesic 
effect, which can be used as an alternative or adjunct to opioids for pain control.
Literature Review
Magnesium sulfate may be beneficial for multimodal pain management as it reduces opioid requirements and 
postoperative pain. Targeting various receptors in the pain pathway can optimize analgesia and reduce side ef-
fects. Magnesium antagonizes the NMDA receptor and blocks calcium channels to modulate pain and inflammato-
ry responses. Perioperative magnesium administration should be considered as a strategy to reduce postoperative 
pain in patients undergoing surgical procedures.
Description of the Case
A 67-year-old female presented for a bilateral breast revision, bilateral blepharoplasty of upper lids, neck rhytid-
ectomy, and fat graft injection surgery. The patient had a history of postoperative nausea and vomiting. During the 
maintenance phase of anesthesia, fentanyl 50 mcg was given as needed for signs of pain, rocuronium was re-dosed 
to maintain paralysis, and ephedrine and phenylephrine were administered to maintain blood pressure. Intrave-
nous magnesium sulfate 2 g was administered as a multimodal approach to analgesia to decrease post-operative 
opioid consumption and to prevent post-operative nausea and vomiting. The following day the patient tolerated a 
regular diet, pain was well controlled, and was hemodynamically stable. The patient was discharged home without 
complications. 
Discussion and Conclusion
Magnesium sulfate may be beneficial for multimodal pain management as it reduces opioid requirements and 
postoperative pain. Magnesium antagonizes the NMDA receptor and blocks calcium channels to modulate pain 
and inflammatory responses. It is unclear which mode of magnesium administration provides an advantage to 
the analgesic effects. The differences in age and gender-related responses to magnesium for analgesia is undeter-
mined. Further research is necessary to examine the use of intravenous magnesium sulfate for postoperative pain 
in different patient populations, safe and effective dosing ranges, and the effects of analgesia in various surgeries. 
Intravenous magnesium sulfate should be considered in multimodal analgesic treatment as an adjunct for postop-
erative analgesia.
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Introduction
§ A multimodal analgesic approach with intraoperative magnesium 
sulfate may reduce opioid consumption in the first 24 hours 
postoperatively and decrease pain scores.1-3
§ Opioids can cause a range of side effects such as respiratory 
depression, postoperative ileus, nausea, vomiting, and 
hypercarbia.1,6,12
§ Inadequate pain relief impacts patient satisfaction and 
contributes to delays in recovery and increased hospital length of 
stay.11
§ Magnesium sulfate may be considered as an adjunct for 
intraoperative analgesia and an alternative to opioid-based 
therapy.
§ Intravenous (IV) magnesium sulfate may minimize postoperative 
pain and decrease opioid consumption.
§ Opioid tolerant patients present a challenge in achieving 
adequate postoperative pain control.6
§ Magnesium sulfate may be implemented to reduce opioid 
reliance and provide time-effective and safe postoperative 
recovery.
§ Magnesium is a noncompetitive antagonist at the N-methyl-D-
aspartate (NMDA) glutamate receptor, which exerts a depressant 
effect (Figure 1).
§ Magnesium prevents central sensitization from peripheral 
nociceptive stimuli at the spinal cord action site by blocking 
NMDA receptors.
§ Magnesium also acts as a calcium channel blocker to inhibit 
calcium influx, which may contribute to the antinociceptive 
effects (Figure 1).
Discussion
§ The presence of a painful stimulus causes the release of glutamate 
and mediates excitatory neurotransmission, which amplifies 
nociceptive stimuli.2 Magnesium is a noncompetitive antagonist at the 
NMDA glutamate receptor, which exerts depressant effects (Figure 
2).14
§ Magnesium is a noncompetitive calcium channel blocker (Figure 1), 
which is one of the mechanisms of antinociceptive activity.
§ Magnesium decreases the pre-synaptic release of acetylcholine (Figure 
1), which reduces the sensitivity of the motor end plate and decreases 
the amplitude of the action potential.2
§ The increase of extracellular magnesium with IV magnesium sulfate 
inhibits the inflammatory response by reducing inflammatory 
cytokines.6
Clinical Rationale: 
§ Magnesium sulfate was given as a multimodal approach to decrease 
the amount of opioids required for pain relief and avoid the opioid side 
effects due to the patient’s history of postoperative nausea and 
vomiting.
Case Critique: 
§ Magnesium sulfate 2 g IV (Figure 4) was given to the patient during 
surgery mixed in a 1 L bag of Plasmalyte infused as the maintenance 
fluid.
§ A bolus of 30 mg/kg of magnesium sulfate before induction was not 
given as mentioned in several of the studies, which may have 
provided additional analgesia.5
§ Currently, there is no standard criteria for perioperative use of IV 
magnesium sulfate.6
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Case Description
§ A 67-year-old, 88 kg, 172 cm, female presented for a bilateral 
breast revision, bilateral blepharoplasty of upper lids, neck 
rhytidectomy, and fat graft injection surgery due to malignant 
neoplasm of the breasts.
§ Past medical history included breast cancer, osteopenia, celiac 
disease, and basal cell carcinoma of the face.
§ Past surgical history included Mohs surgery, breast lumpectomy, 
mastectomy with sentinel node biopsy, and breast reconstruction 
with a tissue expander. 
§ The patient had a history of postoperative nausea and vomiting 
and was given aprepitant 40 mg PO in pre-op.
§ Pre-operative medication: midazolam 2 mg IV
§ Pre-oxygenated with 100% oxygen at 10 L/min with a facemask 
for 5 minutes to reach an expired oxygen concentration of 90%
§ Induction medications: fentanyl 50 mcg IV, lidocaine 100 mg IV, 
propofol 170 mg IV, rocuronium 50 mg IV, ketamine 30 mg IV
§ Maintenance medications: fentanyl 50 mcg IV was given as 
needed for signs of pain, rocuronium IV was re-dosed to 
maintain train of four less than ¾, ephedrine and phenylephrine 
IV were administered to maintain blood pressure within 20% of 
baseline, magnesium sulfate 2 g IV, ketamine 10 mg IV every 
hour, dexamethasone 8 mg IV, acetaminophen 1,000 mg IV, 
sevoflurane at 1.5% in a mixture of oxygen 1 L/min and medical 
air 1 L/min.
§ Emergence medications: sugammadex 200 mg IV and 
ondansetron 4 mg IV
§ Fluid totals: Plasmalyte 2,200 mL, urine output 625 mL, and 
estimated blood loss 25 mL
§ Post-operative course: The patient was transported to the post-
anesthesia care unit with stable hemodynamics. The patient was 
admitted to the hospital to be monitored overnight. The patient 
received acetaminophen 650 mg PO twice for pain control during 
their hospital stay. The following day the patient tolerated a 
regular diet, pain was well controlled, and hemodynamics were 
stable. The patient was discharged home without complications.
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Conclusion/Recommendations
§ Opioids have traditionally been the basis of pain management, 
although significant risks and side effects are associated with opioids.
§ Increased opioid administration is related to a higher incidence of 
respiratory depression, constipation, emesis, confusion, and prolonged 
length of hospital stay.3
§ IV magnesium sulfate bolus of 30 mg/kg before induction followed by 
an intraoperative infusion at 10 mg/kg/hour resulted in significantly 
lower pain scores compared to a placebo group and decreased opioid 
consumption 24 hours following surgery.5
§ Dabbagh et al. found that the group that received magnesium versus 
the control group that received normal saline required significantly 
lower doses of IV morphine in the first 24 hours postoperatively.8 
§ Postoperative administration of magnesium sulfate alone did not 
demonstrate a significant reduction in morphine consumption.12
§ Lysakowski et al. discovered in a systemic review of randomized trials 
for magnesium sulfate as an adjuvant to postoperative analgesia there 
was no evidence that perioperative magnesium had favorable effects 
on postoperative pain intensity and analgesic requirements.13
§ Further research is necessary to examine the use of IV magnesium 
sulfate for postoperative pain in different patient populations, safe and 
effective dosing ranges, and effects on analgesia for various surgeries. 
§ Perioperative magnesium sulfate administration should be considered 
as a strategy to reduce postoperative pain in patients undergoing 
surgical procedures.9
§ IV magnesium sulfate is an alternative analgesic that may be valuable 
in reducing opioid consumption and beneficial for opioid tolerant 
patients.
Safety Considerations for Magnesium Sulfate Administration
§ Avoid magnesium sulfate in patients with renal insufficiency because magnesium is excreted by the kidneys. 
§ Hypermagnesemia and toxicity can occur in renal insufficiency.6
§ Hypermagnesemia can cause sedation, cardiac arrhythmias, diarrhea, respiratory depression, and potentiation of neuromuscular blockade.11
§ Magnesium potentiates neuromuscular blockers; therefore, it should be avoided in patients with neuromuscular diseases because it can 
produce further muscle weakness by inhibiting acetylcholine release.16
§ Magnesium inhibits calcium channels at the presynaptic nerve terminals that trigger the release of acetylcholine (Figure 1). Also, magnesium 
ions have an inhibitory effect on post-junctional potentials and decrease the excitability of the muscle fiber membranes.16
§ The dose of nondepolarizing neuromuscular blockers should be reduced in patients that receive magnesium sulfate and titrated carefully with 
a nerve stimulator to ensure adequate recovery of neuromuscular function at the end of surgery.16
§ Loss of deep tendon reflexes and respiratory or cardiac depression can occur at plasma magnesium concentrations above 10-12 mEq/L.4
§ Magnesium slows sinoatrial node impulses and prolongs conduction time, which can cause heart block and should be avoided in patients with 
atrioventricular conduction abnormalities.4
Figure 1. Magnesium Action Sites 10 
Figure 2. NMDA Receptor Activation 14
Figure 3. IV Magnesium Sulfate 15
Figure 4. Magnesium Sulfate Vials 15
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